Skip to content

Evaluation of the effect of Hesperidin supplementation in patients with myocardial infarction

Evaluation of the effect of Hesperidin supplementation on the serum levels of inflammatory markers (E-selectin, Interlukin 6, hs-CRP) and Adipocytokines (leptin and adiponectin) in patients with myocardial infarction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2012100210181N2
Enrollment
60
Registered
2013-11-27
Start date
2012-10-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardian infarction. Acute myocardial infarction

Interventions

Intervention 1: For the subjects in the intervention group, one capsule included 600 mg pure hesperidin was provided to consume in the morning with breakfast every day for 4 weeks. Intervention 2: the
Treatment - Drugs
For the subjects in the intervention group, one capsule included 600 mg pure hesperidin was provided to consume in the morning with breakfast every day for 4 weeks
the control group received on placebo capsule that was similar the color and shape of hesperidin capsule but included 600 mg starch,in the breakfast for 4 weeks.

Sponsors

Nutrition and Metabolic Diseases Reearch Center in Ahvaz Jundishapur University of Medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria were patients with myocardial infarction, being in the range of 40-65 years old, having body mass index (BMI) from 18.5-30 and patients satisfaction. Exclusion criteria included chronic disease (such as Hepatic disorders, Renal failure, diabetes, et.al.), Gastrointestinal disorders, major psychiatric disorder, taking antidepressants,absolute vegetarian diet, consumption of antioxidant and vitamin supplements at least 6 month before sampling,High consumption of flavonoid-rich beverages (including green tea, coffee, Juice, et.al.), smoking, allergies to any vitamin supplements, lack of patient follow-up and lack of consent.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
IL-6. Timepoint: before intervention and after one month intervention. Method of measurement: plasma levels.;Hs-CRP. Timepoint: before intervention and after one month intervention. Method of measurement: plasma levels.;Leptin. Timepoint: before intervention and after one month intervention. Method of measurement: plasma levels.;Adiponectin. Timepoint: before intervention and after one month intervention. Method of measurement: plasma levels.;E-selectin. Timepoint: before intervention and after one month intervention. Method of measurement: plasma levels.

Secondary

MeasureTime frame
Physical activity. Timepoint: before and end of intervention. Method of measurement: IPAQ questionaire.;Anthropometric indices. Timepoint: before and end of intervention. Method of measurement: meter and scale balance.;Dietary assessment. Timepoint: before, middle and end of intervention. Method of measurement: The three-day, 24-hour food recall.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Haidari

Ahvaz Jundishapur University of Medical Sciences

haidari58@gmail.com+98 61 1373 8383

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026